Cargando…
Nivolumab induced myxedema crisis
BACKGROUND: Nivolumab is an anti-programmed cell death (anti-PD-1) monoclonal antibody that is approved by Food and Drug Administration for treatment of metastatic non-small cell lung cancer, metastatic melanoma, relapsed Hodgkin lymphoma and advanced renal cell cancer. We report a rare case of myxe...
Autores principales: | Khan, Uqba, Rizvi, Humaira, Sano, Dahlia, Chiu, Jane, Hadid, Tarik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5319087/ https://www.ncbi.nlm.nih.gov/pubmed/28239466 http://dx.doi.org/10.1186/s40425-017-0213-x |
Ejemplares similares
-
Composite Lymphoma: Opposite Ends of Spectrum Meet
por: Khan, Uqba, et al.
Publicado: (2017) -
Burn-induced Myxedema Crisis
por: Batista, Ann S., et al.
Publicado: (2017) -
Immunotherapy-associated autoimmune hemolytic anemia
por: Khan, Uqba, et al.
Publicado: (2017) -
Intracerebral Bleeding and Massive Pericardial Effusion as Presenting Symptoms of Myxedema Crisis
por: Kirsch, M., et al.
Publicado: (2017) -
Thyroxine-Induced Preradial Myxedema
por: Chhangte, Mary Zothanpuii, et al.
Publicado: (2019)